Trial Profile
A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at Risk of Fracture
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Abaloparatide (Primary) ; Teriparatide
- Indications Postmenopausal osteoporosis; Vertebral fracture
- Focus Registrational; Therapeutic Use
- Acronyms ACTIVE
- Sponsors Radius Health Inc.
- 01 Apr 2023 Results of post hoc analysis (n=911) of ACTIVE and ACTIVExtend published in the Journal of Bone and Mineral Research.
- 01 Jul 2022 Results of a subgroup analysis described 2D- and 3D-DXA data for hip subregions published in the Journal of Clinical Densitometry
- 04 Nov 2021 According to a Radius Health media release, the company has resubmitted abaloparatide-SC dossier to the EMA for potential approval in the EU.